Lord, Abbett & Co
BIO icon

Lord, Abbett & Co’s Bio-Rad Laboratories Class A BIO Stock Holding History

Lord, Abbett & Co’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-12,045
Closed -$8.98M – 609
2021
Q3 		$8.98M Sell
12,045
-4,524
-27% -$3.39M 0.02% 537
2021
Q2 		$10.7M Sell
16,569
-47
-0.3% -$28.6K 0.03% 521
2021
Q1 		$9.49M Buy
16,616
+2,760
+20% +$1.63M 0.02% 531
2020
Q4 		$8.08M Sell
13,856
-174
-1% -$99.1K 0.02% 562
2020
Q3 		$7.23M Sell
14,030
-162
-1% -$82.1K 0.02% 519
2020
Q2 		$6.41M Buy
14,192
+304
+2% +$134K 0.02% 542
2020
Q1 		$4.87M Buy
+13,888
New +$5.11M 0.02% 539
2018
Q1 		– Sell
-56,900
Closed -$13.6M – 826
2017
Q4 		$13.6M Buy
+56,900
New +$13.8M 0.04% 570

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Lord, Abbett & Co's BIO Position: Q4 2021 in Review

Lord, Abbett & Co sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2021, closing a stake of 12,045 shares — an estimated $8.98M sold.

Lord, Abbett & Co first reported a position in BIO in Q4 2017 and held it in 8 quarters. The position peaked at $13.6M in Q4 2017. 533 funds tracked by Wall St. Rank hold BIO as of Q4 2021.

  • Lord, Abbett & Co reported no remaining Bio-Rad Laboratories Class A position as of Q4 2021 after selling out during the quarter.
  • Lord, Abbett & Co sold 12,045 Bio-Rad Laboratories Class A shares in Q4 2021, an estimated $8.98M.
  • Lord, Abbett & Co first reported a position in Bio-Rad Laboratories Class A in Q4 2017 and held it in 8 quarters.
  • Lord, Abbett & Co's Bio-Rad Laboratories Class A position peaked at $13.6M in Q4 2017.
  • 533 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2021.

Based on Lord, Abbett & Co's 13F filing for Q4 2021, filed 11 Feb 2022.